Peer-reviewed veterinary case report
Novel PPAR-γ Agonist from the Soft Coral <i>Sarcophyton crassocaule</i>: Modulating Glucose Uptake and Lipid Droplet Formation.
- Year:
- 2025
- Authors:
- Zeng JA et al.
- Affiliation:
- School of Ocean and Tropical Medicine · China
Abstract
Two previously undescribed highly oxygenated cembrane-type diterpenes, namely sarcocraol A (<b>1</b>) and sarcocraol B (<b>2</b>), along with five known compounds (<b>3</b>-<b>7</b>), have been isolated from the soft coral <i>Sarcophyton crassocaule</i> collected off Ximao Island in the South China Sea. Their structures were determined through comprehensive spectroscopic analysis, QM-NMR calculations, TDDFT-ECD computation, X-ray diffraction analysis, and by comparison with literature data. Plausible biosynthetic pathways for these compounds were also proposed. All compounds were evaluated for peroxisome proliferator-activated receptors (PPARs) transcriptional activity using luciferase assay. The bioassay results demonstrated that compound <b>1</b> exhibits selective PPAR-γ agonistic activity. Furthermore, it promoted glucose uptake in HepG2 cells by 1.18-, 1.45-, and 1.90-fold at concentrations of 2.5, 5, and 10 μM, respectively, whereas rosiglitazone (10 μM) produced a 2.47-fold increase over the induced control. Compound <b>1</b> at 10 μM induced mild lipid accumulation in 3T3-L1 cells, showing a 1.63-fold increase relative to the control, which was much lower than the 3.28-fold increase observed in rosiglitazone (10 μM) group indicating its potential antidiabetic properties. These findings suggested that compound <b>1</b> could be a promising lead for the development of antidiabetic agents.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication: https://europepmc.org/article/MED/41440884